QLT looks at options for shareholder value

17 December 2007

Vancouver, Canada-based QLT says that its board of directors has engaged Goldman, Sachs & Co as its financial advisor to assist the company in identifying, evaluating and pursuing alternative strategies to maximize shareholder value.

As previously indicated, the special committee of the board, with the advice of Goldman Sachs, will evaluate all opportunities, including transactions involving the sale of all or part of the assets of the company. During the evaluation of specific strategic alternatives QLT does not expect to make comments on its process or progress. In addition, no inference should be drawn if QLT does not respond to individual questions, rumors or press reports concerning its business or activities, the firm stated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight